European Commission Approves Celltrion Healthcare’s Vegzelma™ (CT-P16, biosimilar bevacizumab) for the Treatment of Multiple Types of Cancer
Celltrion Healthcare announced today that the European Commission (EC) has approved Vegzelma™ (CT-P16), a biosimilar bevacizumab referencing EU-approved Avastin®, for the treatment of metastatic breast cancer, non-small cell lung cancer, advanced and/or metastatic renal cell cancer, metastatic carcinoma of the colon or rectum, ovarian cancer and cervical cancer.
“The European Commission’s approval of Vegzelma™ will increase access to treatment for patients living with certain types of cancer at an affordable price,” said Kevin Byoung Seo Choi, Senior Vice President and Head of Marketing Division at Celltrion Healthcare. “With proven similarities in efficacy and safety compared to the reference product Avastin®, Vegzelma™ will be available to treat some of the most commonly diagnosed cancers, which collectively affect hundreds of thousands of European patients each year.”
The EC approval of Vegzelma™ follows the recommendation for marketing authorisation issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) in June 2022.
Today’s approval is based on the totality of evidence, including the phase III pivotal trial in patients with metastatic or recurrent non-squamous non-small cell lung cancer. Results showed that, as a first-line treatment, Vegzelma™ is highly similar to the reference product in terms of efficacy, safety and pharmacokinetics.2
Vegzelma™ (CT-P16) is Celltrion’s third oncology biosimilar approved for use in the EU, following the approval of Truxima® (biosimilar rituximab) and Herzuma® (biosimilar trastuzumab). Vegzelma™ was also filed for regulatory approval with the U.S. Food and Drug Administration (FDA) in September 2021. Approval is expected during the third quarter of 2022.
- ENDS -
Notes to Editors:
About Celltrion Healthcare
Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA Current Good Manufacturing Practice (cGMP) and the EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries. For more information, please visit: https://www.celltrionhealthcare.com
About Vegzelma™ (CT-P16, biosimilar bevacizumab)
Vegzelma™ is an anti-cancer monoclonal antibody treatment biosimilar to Avastin® (bevacizumab). Vegzelma™ is a recombinant humanised monoclonal antibody which binds to VEGF, the key driver of vasculogenesis and angiogenesis, and thereby inhibits the binding of VEGF to its receptors Flt-1 (VEGFR-1), and kinase insert domain receptor (KDR) (VEGFR-2), on the surface of endothelial cells. Neutralising the biological activity of VEGF regresses the vascularisation of tumours, normalises remaining tumour vasculature, and inhibits the formation of new tumour vasculature, thereby inhibiting tumour growth.3 In the EU, Vegzelma™ is indicated for the treatment of patients with metastatic colorectal cancer, non-small cell lung cancer, metastatic renal cell carcinoma, ovarian cancer, advanced cervical cancer and metastatic breast cancer.
References
1 Avastin is a registered trademark of Genentech Inc.
2 Ohe Y et al., Randomized Phase III Study Comparing the Efficacy and Safety of CT-P16, a New Biosimilar, to Reference Bevacizumab (Avastin) In Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC). Proceedings: American Association for Cancer Research (AACR) Annual Meeting 2022; April 8-13, 2022 New Orleans, Louisiana.
3 European Medicines Agency Summary of Product Characteristics (SmPC), Avastin. Available at https://www.ema.europa.eu/en/documents/product-information/avastin-epar-product-information_en.pdf [Last accessed August 2022].
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220817005324/en/
Contact information
Holly Barber
hbarber@hanovercomms.com
+44 (0) 07759 301620
Donna Curran
dcurran@hanovercomms.com
+44 (0) 7984 550312
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PPG sets paint stirring world record at SEMA 2025 to highlight benefits of new automated system for body shops5.11.2025 20:41:00 EET | Press release
PPG (NYSE: PPG) today announced that it achieved a GUINNESS WORLD RECORDS™ title for the largest simultaneous paint stirring challenge during a customer event at the 2025 SEMA Show in Las Vegas. More than 275 participants stirred paint together to highlight the manual effort still common in collision repair before PPG unveiled its new SEM MIX’N’SHAKE™ automated stirring solution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105923792/en/ More than 275 participants simultaneously stirred paint at SEMA 2025 as PPG breaks the GUINNESS WORLD RECORDS™ title for the largest paint stirring challenge as it unveiled the SEM Mix’n’Shake™ automated stirring system. The SEM Mix’n’Shake system produces a fully homogenized car paint mix in less than 60 seconds. By automating this step, body shops can reduce rework and recover up to 6% more productive work hours annually. The system also improves paint consistency, efficiency and work
Quectel Unveils New Smart Single Board Computers (SBC) to Help Accelerate Intelligent Device Development, Rapid Prototyping and Cutting Development Costs5.11.2025 19:00:00 EET | Press release
Quectel Wireless Solutions, an end-to-end global IoT solutions provider, has launched three new smart single board computers (SBC). The QSM368Z, QSM560DR, and QSM668SR are designed to give developers more choice and speed up product development of intelligent solutions and digital transformation. Each board is cost-effective, fully certified, and offers a wide range of options for connectivity, operating system and memory options to suit different application needs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105179097/en/ Quectel unveils new smart single board computers (SBC) to help accelerate intelligent device development, rapid prototyping and cutting development costs “These boards are fully finished hardware that can be easily integrated inside customers’ larger systems across a wide range of IoT use cases,” commented Raymond Wang, Head of Smart SoC, Quectel Wireless Solutions. “Provided in a ready-to-use, singl
First in Human Ischemic VT Ablation Successfully Performed in iCMR5.11.2025 17:55:00 EET | Press release
Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR), together with Amsterdam University Medical Centre (Amsterdam UMC), is pleased to announce the successful completion of the first Ischemic Ventricular Tachycardia (VT) ablation ever performed under real-time MRI guidance in an iCMR lab. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105120761/en/ Imricor’s NorthStar® Mapping System The Amsterdam UMC team, shown here, performed the VT ablation procedure following previous experiences performing atrial flutter and premature ventricular complex (PVC) ablation procedures guided by real-time MRI and Imricor’s NorthStar® Mapping System. Regarding the VT procedure, Dr. Kemme, stated: “This procedure is part of an international research programme. The MRI imaging shows us precisely where the myocardial infarction took place; therefore, we can send the catheter to the exact spot. This information can make ablation possi
SIS Medical AG Welcomes the Results of the VICTORY Trial Demonstrating Non-inferiority of OPN NC to Intravascular Lithotrispy (IVL) for Lesion Preparation and Stent Expansion in Severely Calcified Lesions5.11.2025 17:12:00 EET | Press release
SIS Medical AG, a Swiss manufacturer of the Super-High-Pressure PTCA balloon catheter (OPN NC), is pleased to announce that the results of the investigator-initiated VICTORY trial were presented during the late-breaking clinical session at TCT 2025 by the Cardiovascular Research Foundation (CRF). The randomized, multi-center clinical study was designed to compare the safety and efficacy between the OPN and IVL devices for lesion preparation and optimized stent expansion in highly complex calcified coronary lesions, deploying a drug-eluting stent (DES). Coronary artery calcium affects approximately one-third of patients undergoing PCI and is a key contributor to procedural and stent failure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105812157/en/ "With a similar safety profile, OPN can be a feasible and faster alternative to IVL." Dr. M. Bossard, Senior Physician at Luzerner Kantonsspital, Switzerland A total of 282 p
Doha Debates Explores the Role of Ancient Wisdom in Today’s World5.11.2025 17:06:00 EET | Press release
As the world grapples with questions of meaning and moral direction, Doha Debates takes on a fundamental question: Should ancient wisdom guide today’s societies? This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105183709/en/ Guest speakers and participating students gather on the Doha Debates stage to discuss a fundamental question “Should ancient wisdom guide today’s societies?” — part of the show’s exploration of timeless questions shaping our world today. (Photo: AETOSWire) In this episode of the new flagship season, moderated by Dareen Abughaida, students from across Qatar join three global thinkers to wrestle with a timeless dilemma: whether the answers to our most pressing problems lie in tradition or in bold new ideas. Wael Hallaq, Avalon Foundation Professor in the Humanities at Columbia University, critiques what he calls the “moral emptiness” of modernity and its fixation on material progress. He calls for a retur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom